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Received 12 August 2014; revised 17 August 2014; accepted 1 September 2014AbstractGenetic defects are one of the most important etiologies of severe to profound sensorineural hearing loss and play an important role in
determining cochlear implantation outcomes. While the pathogenic mutation types of a number of deafness genes have been cloned, the
pathogenesis mechanisms and their relationship to the outcomes of cochlear implantation remain a hot research area. The auditory performance
is considered to be affected by the etiology of hearing loss and the number of surviving spiral ganglion cells, as well as others. Current research
advances in cochlear implantation for hereditary deafness, especially the relationship among clinic-types, genotypes and outcomes of cochlear
implantation, will be discussed in this review.
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a rate of 3/1000 live births. About 1/1000 children exhibit
hearing loss before school age. Over 60% of pre-lingual
deafness is related to hereditary factors, while the rest is
attributed to environmental or iatrogenic factors. Nowadays,
newborn deafness gene screening for potential early inter-
vention is a common practice all over the world. Conventional
amplification devices may benefit some patients with heredi-
tary deafness, but not for all types of hearing loss. Some pa-
tients with hereditary hearing loss need cochlear implant to
acquire useful hearing. To examine outcomes of cochlear
implant in various types of hereditary deafness, literatures on
hereditary deafness are reviewed extensively, including syn-
dromic and non-syndromic deafness. Most reports found in the
relevant literatures are case reports or small cohort cochlear
implant studies, with less than conclusive evaluation on the
overall outcomes for hereditary deafness. The current reportsE-mail address: x.liu1@med.miami.edu.
Peer review under responsibility of PLA General Hospital Department of
Otolaryngology Head and Neck Surgery.
http://dx.doi.org/10.1016/j.joto.2015.01.001
1672-2930/Copyright © 2015, PLA General Hospital Department of Otolaryngolog
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativattempt to assess indications and treatment outcomes of
cochlear implant in various types of hereditary deafness in
relations to their clinical manifestation, genetic etiologies and
temporal bone pathology.1. Deafness related to the Cx26 and Cx30 genes
Connexin is an important component of the connecting
channels in cellular gap junction, facilitating intercellular
electrolytes exchange. Of the known 21 types of connexins,
five are expressed in the mammalian cochlea. Regulation of
electrolytes across cellular membranes and balance of potas-
sium gradient inside and outside cells in the cochlear spiral
ganglion and stria vascularis cells are crucial for the genera-
tion of hair cell action potentials. Connexin dysfunction leads
to potassium retention and microcirculation disorders, subse-
quently resulting in hair cell malfunction and degeneration
(Propst et al., 2006). In addition to regulating intra- and
extracellular potassium concentrations, in vitro studies have
shown that channels involving Cx26 may participate in
transporting secondary messenger IP3 which regulates Caþþy Head and Neck Surgery. Production and hosting by Elsevier (Singapore) Pte
ecommons.org/licenses/by-nc-nd/4.0/).
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Caþþ move faster than in cells with other types of channels.
Mutation of Cx26 genes can result in disordered Caþþ
movement and distribution in tissues (Beltramello et al.,
2005). Cx26 gene mutations, however, do not affect vestib-
ular functions.
At this time, more than 100 types of mutation have been
reported regarding Cx26, with certain racial features. For
example, c.235delC (or c.233delC) is mostly seen among
Asians, c.35delG (or c.30delG) among Caucasians, and
c.167delG among Jews. These are all frame shift mutations,
leading to premature ending of protein synthesis and hence
dysfunction of connexins.
Studies in China that compare cochlear implant treatment
outcomes in patients with and without Cx26 gene mutations
show that results in those with Cx26 are superior to those
without regarding meaningful auditory integration scale,
auditory behavioral grade, speech intelligibility and stan-
dardized speech learning period assessment (Yan et al., 2011).
Matsushiro et al. (2002) evaluated cochlear implant outcomes
in four Japanese children with homogenous Cx26 233delC
mutation and profound hearing loss, and reported that speech
understanding in these children were better than in deafness
patients without Cx26 mutation. In addition to c.235delC
mutation, multiple studies on non-syndromic deafness have
also demonstrated better results in deafness patients with
35delG mutation than in those without, showing faster
improvement in speech and speech understanding with better
consistency. Reading capability studies have shown that pa-
tients with Cx26 mutations do not carry other complicating
etiologies, such as disorders of the VIII cranial nerve, central
auditory structures or cognitive centers at higher levels
(Connell et al., 2007; Bauer et al., 2003). Propst et al. (2006)
studied electrically evoked auditory nerve compound action
potentials in patients with cochlear implant and found that
intact spiral ganglion cells were present inside the cochlea in
patients with Cx26 mutations. However, Cx26 mutations are
not the sole accurate indicator of cochlear implant outcomes
(Connell et al., 2007; Bauer et al., 2003). Compared to chil-
dren with Cx26 mutations as the clear etiology for deafness,
structural and molecular etiologies for deafness in non-
DFNB1 children are more complex. Statistical analysis sug-
gests that the length of implanted electrodes may be a better
indicator of cochlear implant outcomes than hereditary factors
(Connell et al., 2007).2. PDS (SLC26A4) gene-related deafness
The earliest records of Pendred syndrome (PDS) were two
Irish sisters presenting with thyroid goiters and deafness (hence
also known as goiter-deafness syndrome). The responsible gene
is PDS (SLC26A4) which encodes an iodide/chloride trans-
porter protein called pendrin in the solution carrier family.
Pendrin is found in both thyroid and cochlea. Usami et al. (1999)
showed that the PDS gene was also responsible for large
vestibular aqueduct syndrome (LVAS). There are about 140types of PDS mutations discovered among patients with PDS or
LAVS,with IVS7-2A>Gand p.H723Rbeing themost common
among East Asia populations (Dai et al., 2008; Pare et al., 2005).
Non-syndromic deafness patients carrying PDS double
mutant alleles often manifest severe fluctuating hearing loss,
but it is unclear if PDS mutations increase hearing loss
severity or how enlarged vestibular aqueduct is related to
hearing loss. Research indicates that PDS mutations lead to
changes in pendrin protein structure and function, resulting in
disorders in chloride transportation and inner ear fluid circu-
lation, and subsequently enlarged vestibular aqueduct and
increased endolymphatic pressure, which can cause hair cells
damage and hearing loss (Kraiem et al., 1999). There are
several speculations on the pathogenesis of hearing damage in
LVAS. Some suggest that enlarged vestibular aqueduct dis-
turbs endolymphatic circulation, resulting in high osmotic
pressure in the endolymphatic sac and retrograde flow into the
cochlea which causes damage to cochlear neuroepidermal
cells and subsequently neural hearing loss. Others believe that
there are weak fragile areas in the vestibule in patients with
LVAS which may break when sustaining trauma or sudden
CSF pressure change, leading to mix of endo- and peril-
ymphatic fluids or perilymph fistula, and subsequently neural
hearing loss (Xu and Chi, 2003).
For patients with PDS mutations and severe or profound
hearing loss, cochlear implant is an effective treatment to
improve hearing. Cochlear implant started in 1992 and has
seen significant improvement in implant devices and surgical
techniques since first two successful cases in 1995, with
overall improved outcomes. Since children with enlarge
vestibular aqueduct tend to have gradually increasing hearing
loss, they show a much broader range of age at first implant
compared to those with congenital severe or profound hearing
loss. Research, however, shows that postoperative hearing
thresholds in these children are not significantly different from
those in patients with normal inner ear anatomy (El-Amraoui
and Petit, 2005).3. Usher syndrome
Usher syndrome is a recessive autosomal hereditary disease
with dysfunction of both the ear and eye, manifested as
congenital sensorineural hearing loss and progressive
pigmentary retinitis and later retinal degeneration. At an age
of 2e4 years, retinal electrophysiology test can show abnor-
malities with the photoreceptors, night blindness shows up at
10 years of age with loss of vision field, and finally the patient
becomes blind during teen years (Rosenberg et al., 1997).
Usher syndrome is the most common deafnesseblindness
syndrome in human.
Based on its clinical presentation, Usher syndrome can be
classified in three types. Type I (UshI) is the most severe type
and accounts for 30e40% of Usher syndrome cases. It is
characterized by congenital severe to profound hearing loss at
birth, vestibular dysfunction and impaired activity develop-
ment at very young age, and progressive retinal pathological
158 X. Liu / Journal of Otology 9 (2014) 156e162changes with vision deterioration e from loss of peripheral
vision and central visual field sensitivity at a young age to
complete blindness in early adulthood. Residual low frequency
hearing in this type of Usher syndrome is usually in the range
of 90e100 dB HL, unable to benefit from hearing aids and
requiring cochlear implant.
UshI patients demo nstrate abnormal vestibular functions
and electroretinograms at an early stage (Loundon et al.,
2003). However, electroretinography is a sophisticated test
requiring general sedation in children and therefore not
routinely used in the clinic (Liu et al., 2008). Pennings et al.
(2006) conducted gene tests in 14 CI patients and found
mutations in half of these patients. They concluded that gene
testing could be used as one of the early diagnosis options in
these patients. Molecular studies on USHI mutations show
that all defective proteins appear during the time of formation
of auditory hair bundles (kinocillia and sterocillia). UshI
defective proteins (myosin VIIa, PDZ domain containing
protein Harmonin, cadherin 23, pro-cadherin 15 and scaf-
folding protein Sans) are believed to be involved in the for-
mation of hair bundle connection and adhesion. Disturbed hair
bundle structures have been reported in rats lacking UshI
homologous gene proteins (El-Amraoui and Petit, 2005).
Wagenaar et al. (2000) examined two UshI patients and found
severe degeneration in the cochlea with atrophy of the
basal turn and stria vascularis and decreased number of
spiral ganglion cells. In contrast to their normal counterparts,
the rate of their cochlear neurons decay is as high as 68%
on average, and severe degeneration of the macula sacculi can
be seen in patients with genetically Ush1D or Ush1F
diagnosis.
Age is probably the most critical prognostic indicator in
cochlear implant for Usher syndrome. Usher syndrome can
cause dysfunction of both auditory and visual organs, and
while sign language communication is possible at early ages, it
eventually becomes impossible after loss of vision and the
patient has to rely on verbal communication. Cochlear implant
is therefore especially important as a way to acquire hearing
and speech functions in these patients. Liu et al. (2008)
compared speech rehabilitation results following cochlear
implant among a group of patients with USHI syndrome aging
from 2 to 15 years. Both open and closed sets word test scores
showed the greatest increase in children <3 years of age when
receiving cochlear implant than in those receiving implant at
an age older than 6 years, indicating that early intervention
before loss of vision is crucial to development of effective
hearing and speech capabilities. Blanchet et al. (2007) showed
that children who received cochlear implant before 3 years of
age were able to benefit from regular education. Loundon et al.
(2003) concluded that cochlear implant before 9 years of age
yielded significant benefits, with all patients (100%) showing
statistically significant improvement in open set word test
scores, although only 25e75% in closed set scores. Further-
more, Young et al. (1995) concluded through their research
that cochlear implant outcomes were also related to the degree
of hearing loss as well as the type and intensity of rehabili-
tation. Clinical phenotype does not appear to be closely linkedto types of genetic mutation in UshI syndrome (Blanchet et al.,
2007).4. Mitochondria-related deafness
Mitochondria DNA encodes numerous messages as well
as tRNA and is at the core in coding production of ATP,
which provides energy in almost all organs but especially
those at high rate of metabolism. Cochlear outer hair cells
and the stria vascularis are high metabolism structures.
Motion of hair bundles of hair cells comes from intra-
cochlear action potentials that are maintained by the Naþ/
Kþ-ATP pump in the stria vascularis. The basal turn of the
cochlea, which responds to high frequency sounds, exhibits
even higher metabolic needs than other parts of the cochlea.
Mitochondrial dysfunction affects high frequency hearing
first, followed by spreading to other frequencies and even-
tually hearing loss at all frequencies (Sinnathuray et al.,
2003).
Studies with temporal bone histology show that outer hair
cells suffer more rapid and severe damages than inner hair
cells when the number of spiral ganglion cells declines and
that cochlear dysfunction progresses from the basal to apical
turns (Yamasoba et al., 1999).
Mitochondrial deafness can be syndromic or non-
syndromic. Those relevant to cochlear implant include
“mitochondrial encephalopathy, lactic acidosis, and stroke-like
episodes (MELAS) syndrome”, maternally inherited diabetes
and deafness (MIDD) syndrome, KearnseSayre syndrome
(KSS), chronic progressive external ophthalmoplegia (CPEO)
syndrome, etc. Non-syndromic mitochondrial deafness is more
common than syndromic and often related to aminoglycoside
ototoxicity, especially in the A1555G mutation (Sinnathuray
et al., 2003; Prezant et al., 1993). Cochlear implant out-
comes are generally good in cases of non-syndromic mito-
chondrial deafness. Tono et al. (1998) reported a case of
A1555G mutation. The patient acquired sensorineural hearing
loss 28 years ago following using aminoglycoside drugs and
achieved 78% (54% when blinded) monosyllable test scores
and 84% (76% when blinded) word test scores 10 months after
cochlear implant. Ulubil et al. (2006) presented a 35 years old
patient with hearing loss and A1555G mutation but no history
of aminoglycoside exposure. At 1 month following cochlear
implant, his average open set CUNY score was 60% (65% in
HINT). Results in syndromic deafness cases are also encour-
aging. In a case of MELAS reported by Rosenthal et al.
(1999), the 20 years old male patient achieved a 60% CID
sentence test score at 6 months after cochlear implant. In a
report by Yasumura et al., the 29 years old female patient
demonstrated 72% and 94% scores in closed set word and
sentence tests respectively, and 44% and 34% scores in open
set testing, at 10 months postoperatively (Karkos et al., 2005).
Cochlear implant is also effective in MIDD syndrome. A 42
years old woman in a report by Raut et al. (2002) produced a
90% BKB sentence test score. Similarly, Counter et al. (2001)
reported a patient with MIDD syndrome, whose CUNY score
159X. Liu / Journal of Otology 9 (2014) 156e162increased from 5% to 84% at 3 months following cochlear
implant.
5. Waardenbury syndrome (WS)
WS is a relatively common autosomal hereditary syndrome,
also known as auditoryepigmentary syndrome. Its clinical
features include inner canthus shift, thick eye brow, hetero-
chromia iridium, premature canities and sensorineural hearing
loss of various degrees. The rate of WS among newborns is
about 1/40,000 and accounts for about 2e5% of congenital
deafness (Cullen et al., 2006; Nayak and Isaacson, 2003) (but
only 0.44e0.46% in China (Gao et al., 2000; Yang et al.,
2010)). Clinically, there are 4 subtypes within WS. Type I
carries inner canthus shift, sensorineural hearing loss, heter-
ochromia iridium, premature canities, hypopigmentation,
synophridia, etc. There is no inner canthus shift in type II.
Type III, also known as Klein-Waardenburg syndrome, adds
upper extremity muscle dysplasia and contracture, in addition
to features in type I. Type IV is also called Shah-Waardenburg
syndrome and adds congenital megacolon to type II (Nayak
and Isaacson, 2003). Types I and II are the most commonly
seen both in China and abroad. The pathogenic gene is PAX3
(a transcription factor) in the former and MITF in the latter,
which encodes a tyrosinase catalyst that is critical in melanin
production and interacts with the PAX3 gene (Watanabe et al.,
1998). The pathogenesis in WS may be related to lack of
melanocytes in the stria vascularis. Mutations of relevant
genes cause disruption in melanin production and can affect
the hair, skin and eye, as well as deposit of melanin in neural
crest cells which is the foundation of formation of stria vas-
cularis (seen as atrophy of the Organ of Corti and stria vas-
cularis on temporal bone histology) (Watanabe et al., 1998;
Nakashima et al., 1992). Cochlear implant has been used as
an intervention in WS with profound sensorineural hearing
loss. Bony labyrinth anomaly is not common in WS, but can
present as abnormal or missing semicircular canals, which
calls for caution during implant procedures but is not a
contraindication (Zhang et al., 2009).
WA patients have shown above average results in post-
implant closed and open set word tests. Reports from China
and overseas have stated that WS patients enjoy better
cochlear implant outcomes than those with inner ear malfor-
mation or non-syndromic deafness with “normal” cochlea
(Zhang et al., 2009; Cullen et al., 2006). In a report from
University of North Carolina at Chapel Hill, five of the seven
patients who had received cochlear implant showed 100%
closed set word recognition score and greater than 50% open
set word recognition scores soon after implantation (Cullen
et al., 2006). A follow up report on WS1 patients from Iran
showed similar results, with all children being able to attend
regular education. However, Pau et al. (2006) noticed that in
20% of 20 WS cases implanted between 1985 and 2001, ABR
results were abnormal. They concluded that the significantly
worse speech recognition results were related to “co-existing”
auditory neuropathy that adversely impaired cochlear implant
outcomes.6. JervelleLangeeNielse syndrome (JLNS)
JLNS is featured by emotional syncope, sudden death,
arrhythmia and congenital sensorineural hearing loss, with
seizure from severe bradycardia or ventricular tachycardia
being frequently seen (Siem et al., 2008). On ECG, QT in-
terval is often >0.44 s in male patients and >0.46 s in female
patients, which can lead to ventricular tachycardia/fibrillation
or torsive ventricular tachycardia or even sudden death, often
triggered by excitement, strenuous exercise or noise that leads
to high levels of catecholamine release (as seen when swim-
ming in about 16% of such cases) (Chorbachi et al., 2002;
Daneshi et al., 2008). b blockers are often used to control
arrhythmia, while pace-maker and defribrillator implants are
used to reduce sudden death (Chorbachi et al., 2002; Yanmei
et al., 2008).
JLNS-related genes are KCNQ1 and KCNE1 (LQT1), both
encode the slow components in the delayed rectifier Kþ
channel compound (90% and 10% respectively). Delayed
rectifier Kþ channels pump Kþ out of stia vascularis cells to
maintain Kþ stability in the endolymph (Neyroud et al.,
1997). Temporal bone histology studies have shown collapse
of Reissner's membrane, saccule, utricle and membranes near
the ampulla which can lead to blockage of the endolymphatic
system in the scalae tympani and vestibuli (Friedmann et al.,
1968).
CI is considered an effective treatment for deafness from
JLNS. As mentioned above, cochlear implant bypasses the
dysfunctional Organ of Corti and stimulates the spiral gan-
glion directly. Chorbachi et al. (2002) presented a case of
JLNS in three brothers born to parents in a consanguineous
marriage, all with congenital profound deafness and pro-
longed QT intervals. The two younger brothers enjoyed good
hearing results from cochlear implant. Yanmei et al. (2008)
reported a 3 years old child who achieved a CAP score of 7
and a SIR score of 5 at 36 months after cochlear implant. In a
follow up study by Daneshi et al. (2008) with three children
younger than 3 years, the CAP and SIR scores were 6 and 4,
respectively, at 48 months after cochlear implant, and all
three children were able to attend regular education. Some
literatures have reported symptoms of vestibular involvement
in JLNS. Green et al. (2000) reported a child whose open set
word test scores and articulation improved following
cochlear implant but demonstrated a delay in speech devel-
opment compared to normal children by about 1.5 years.
Siem et al. (2008) reported a series of 8 children aged from
17 months to 7.5 years who had undergone cochlear im-
plantation. Two of these children died of heart conditions and
the rest children showed good hearing test results, although
with delayed gross motor function development that might
indicate involvement of the vestibular system. In the 1960s,
Friedmann et al. (1968) observed fibrosis and dysplasia of
vestibular epithelium on temporal bone histology. However,
our understanding of vestibular involvement in JLNS remains
limited even today.
For patients with JLNS, QT interval evaluation before
cochlear implant is important and preoperative ECG test is
160 X. Liu / Journal of Otology 9 (2014) 156e162considered necessary in patients with congenital hearing loss
to prevent potential cardiac complications. Anesthetics with
anti-arrhythmia properties should be carefully selected and b
blockers are usually needed. For those whose torsive tachy-
cardia can be triggered by noise, induction should be con-
ducted in a quiet environment. With careful preparation for
possible adverse incidents, safe implant procedures for
improved hearing in these patients are feasible.7. Auditory neuropathy (AN)
Auditory neuropathy (AN) is a hearing disorder caused
by dysfunction of the inner hair cell/auditory nerve
synapse and/or the auditory nerve itself, with essentially
normal functioning from the external ear canal to outer hair
cells. It has unique clinical presentations and audiometric
features, and is also called auditory nerve spectrum disorder
(ANSD) for its rather complex etiologies (Manchaiah et al.,
2011).
ANSD can be classified as non-syndromic and syndromic,
with the non-syndromic type being more common and pre-
senting with simple hearing disorders without other neuro-
logical abnormalities in contrast to the syndromic type which
presents with other neurological disorders in the form of a
syndrome. Etiologies for AN are complex and hereditary
factors play an important role. Non-syndromic ANSD is
often associated with OTOF, DIAPH3 and PJVK genes, and
GJB2 and mitochondrial DNA 12rRNA genes have also been
reported in AN, although rare (Santaretlli et al., 2008; Wang
et al., 2005). The OTOF gene encodes the protein otoferlin
which plays an important role in promoting exocytosis of
auditory ribbon synapse vesicles. Its mutation can result in
DFNB9. The DIAPH3 gene encodes a hyaline protein com-
pound that is important to cellular morphology polarity and
adhesion, and its mutations can lead to over-expression of
the protein and AN. The PJVK gene encodes Pejvakin which
is expressed in the afferent neurons in the cochlea and
auditory pathway, and its mutations affect activities of hair
cells and auditory neurons, leading to DFNB59 (Bae et al.,
2013).
AN is characterized by absent or abnormal ABRs with
preserved cochlear responses (OAEs and CMs). Hearing loss
on pure tone audiometry in patients with AN is usually
bilateral and may vary from mild to profound in severity, often
with flat or ascending curves on audiogram, although other
patterns are also possible. Speech recognition in these patients
is usually poor, even with only mild or moderate loss on pure
tone audiometry.
Cochlear implant for ANSD has been controversial,
although good results have been reported in some patients.
Recent years have seen increasing reports of satisfactory
outcomes with cochlear implant in ANSD patients. Pelosi
et al. (2013) compared InfanteToddler Meaningful Auditory
Integration Scale (IT-MAIS) and open set word test results
among patients diagnosed with ANSD at Vanderbilt University
between 2009 and 2011who either were fitted with hearingaids with satisfaction or received cochlear implant after failing
hearing aids, and found no significant difference between the
two groups. They therefore concluded that cochlear implant
may help improve speech recognition in patients who cannot
benefit from hearing aids. Budenz et al. (2013) studied
cochlear implant outcomes in children with AN only and in
those with AN complicated with cognition development dis-
orders, and found outcomes in the former are superior to those
in the latter and similar to those in children who have received
cochlear implant for cochlear disorders. Breneman et al.
(2012) also concluded that cochlear implant outcomes in
children with ANSD but preserved auditory nerve were not
different from those in non-ANSD children, although some
studies show that vowel recognition is slightly worse with
significantly worse consonant recognition in the former than in
the latter following cochlear implant (Miyamoto et al., 1999).
Currently, it is believed that outcomes in patients with ANSD
are related to the location of the ANSD lesion and the number
of spiral ganglion cells involved. Poorly developed, absent or
atrophied cochlear nerve can adversely affect cochlear implant
outcomes. Preoperative imaging for auditory nerve develop-
ment evaluation and EABR assessment of spiral ganglion cells
may be necessary before cochlear implant in ANSD patients
(Wang and Yin, 2006).
Hereditary factors are an important etiology for deafness.
Many genetic etiologies for deafness have been determined
and characterized, including Cx26 mutation related deafness,
PDS-related deafness, Usher syndrome, mitochondrial
DNA-related deafness, Waardenburg syndrome, Jer-
velleLangeeNielsen syndrome, etc. Etiologies for AN are
complex, and only a few non-syndromic etiologies have been
determined. From reviewing the literature, contraindications
to cochlear implant are rare and may include advanced age
and inability to pronounce. Cochlear implant intervention,
especially early intervention, in individuals with hereditary
deafness, can result in obvious hearing and speech rehabili-
tation as the spiral ganglion and central pathways remain
relatively intact. Further studies involving large hereditary
deafness populations are needed to confirm the efficacy of
cochlear implant in these patients. Even more important is
appropriate genetic screening and consultation in individual
deafness patients. In summary, genetic studies remain a
forefront in medical science research and expanding
exploration into genetic etiologies for human diseases is
extremely valuable while certainly facing numerous unknown
challenges.References
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